Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of SHR-3045 Injection in Patients With Moderate to Severe Active Rheumatoid Arthritis

NCT07233655 is registered in ClinicalTrials.gov with Guangdong Hengrui Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07233655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07233655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of SHR-3045 Injection in Patients With Moderate to Severe Active Rheumatoid Arthritis
Lead sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 19, 2026
Completion date
July 31, 2026
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe active rheumatoid arthritis